Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod vs Fingolimod in Pediatric Relapsing Remitting Multiple Sclerosis
NCT06408259Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2025
- Primary completion
- Apr 2031
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of ozanimod in multiple sclerosis (MS), sponsored by Bristol Myers Squibb. Started Apr 2025; status: recruiting.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06408259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06408259.